ChemicalBook > CAS DataBase List > Ciprofibrate

Ciprofibrate

Ciprofibrate Structure
Ciprofibrate
  • CAS No.52214-84-3
  • Chemical Name:Ciprofibrate
  • CBNumber:CB0329743
  • Molecular Formula:C13H14Cl2O3
  • Formula Weight:289.15
  • MOL File:52214-84-3.mol
Ciprofibrate Property
  • Melting point 114-116°
  • Boiling point 401.74°C (rough estimate)
  • Density 1.2576 (rough estimate)
  • refractive index 1.5209 (estimate)
  • storage temp. 2-8°C
  • solubility Practically insoluble in water, freely soluble in anhydrous ethanol, soluble in toluene.
  • pka 3.31±0.10(Predicted)
  • form Solid
  • color White to Pale Beige
  • Merck 14,2313
  • InChI InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
  • InChIKey KPSRODZRAIWAKH-UHFFFAOYSA-N
  • SMILES C(O)(=O)C(OC1=CC=C(C2CC2(Cl)Cl)C=C1)(C)C
  • CAS DataBase Reference 52214-84-3(CAS DataBase Reference)
  • FDA UNII F8252JGO9S
  • ATC code C10AB08
  • EPA Substance Registry System Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl- (52214-84-3)
  • UNSPSC Code 41116107
  • NACRES NA.77
Safety
  • Hazard Codes  :T
  • Risk Statements  :45
  • Safety Statements  :53-22-36/37/39-45
  • WGK Germany  :3
  • RTECS  :UF0880000
  • HS Code  :29189900
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H350
  • Precautionary statements P201-P308+P313
Ciprofibrate Price More Price(3)
  • Brand: Sigma-Aldrich(India)
  • Product number: C0330
  • Product name : Ciprofibrate
  • Purity: 
  • Packaging: 10MG
  • Price: ₹17135.98
  • Updated: 2022/06/14
  • Buy: Buy
  • Brand: TCI Chemicals (India)
  • Product number: C2667
  • Product name : Ciprofibrate
  • Purity: min. 98.0 %
  • Packaging: 1G
  • Price: ₹6500
  • Updated: 2022/05/26
  • Buy: Buy
  • Brand: TCI Chemicals (India)
  • Product number: C2667
  • Product name : Ciprofibrate
  • Purity: min. 98.0 %
  • Packaging: 5G
  • Price: ₹13900
  • Updated: 2022/05/26
  • Buy: Buy

Ciprofibrate Chemical Properties,Usage,Production

  • Description Ciprofibrate is a potent, long-acting hypolipidemic agent related to clofibrate, bezafibrate and fenofibrate. It is effective in types IIa, IIb, IIX and IV hyperlipoproteinemias, and produces a beneficial elevation of the anti-atherogenic HDL.
  • Description Ciprofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα; EC50 = 0.9 μM in a transactivation assay). It is selective for PPARα over PPARγ and PPARδ at 300 μM. Ciprofibrate (250 μM) induces cell cycle arrest at the G2/M and S phases in Fao rat, but not HepG2 human, hepatocellular carcinoma cells. It decreases fasting plasma levels of triglycerides and increases fasting plasma glucose levels in the apolipoprotein CIII transgenic mouse model of hypertriglyceridemia when administered at a dose of 10 mg/kg. Formulations containing ciprofibrate have been used in the treatment of hypertriglyceridemia.
  • Chemical Properties Off-White to Pale Beige Solid
  • Originator Sterling-Wintbrop (USA)
  • Uses antihyperlipidemic
  • Uses Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor involved in the regulation of lipid homeostasis. Activation of PPARα results in expression of a variety of genes, particularly those involved in fatty acid β-oxidation, binding, and transport. Ciprofibrate activates PPARα with an EC50 value of 20 μM and only marginally affects PPARγ (EC50 = >300 μM). It has been shown to lower adipose tissue weight and reduce plasma insulin concentrations in obese rats and has been used clinically in the treatment of dyslipidemia. Ciprofibrate reportedly stimulates cholesteryl ester transfer protein expression and improves the flow of cholesterol through the indirect reverse cholesterol transport system, preserving plasma HDL.
  • Uses Ciprofibrate is a hypolipemic agent, related structurally to Clofibrate (C586910). Ciprofibrate is used as an antilipemic.
  • Definition ChEBI: Ciprofibrate is a monocarboxylic acid, a member of cyclopropanes and an organochlorine compound. It has a role as an antilipemic drug.
  • Manufacturing Process A mixture of 8 g (0.0356 mol) of p-(2,2-dichlorocyclopropyl)phenol, 11.2 g (0.28 mol) of sodium hydroxide pellets, 11 g of chloroform and 350 ml of acetone was prepared at 0°C. The cooling bath was removed, the mixture stirred for a minute and then heated on a steam bath to reflux temperature. The reaction mixture was stirred at reflux for three hours and then concentrated in vacuo. The residual gum was partitioned between dilutehydrochloric acid and ether, and the ether layer was separated, dried and concentrated in vacuo. The residual oil (14 g) was partitioned between dilute aqueous sodium bicarbonate and ether. The sodium bicarbonate solution was acidified with concentrated hydrochloric acid and extracted with ether. The ether solution was dried over anhydrous sodium sulfate and concentrated. The residue (9.5 g of yellow oil) was crystallized twice from hexane to give 6.0 g of 2-[p-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl propionic acid in the form of a pale cream-colored solid, MP 114°C to 116°C.
  • brand name LJPANOR
  • Therapeutic Function Antihyperlipidemic
  • World Health Organization (WHO) The safety profile of ciprofibrate is similar to that of clofibrate. See also under clofibrate in full edition.
  • Biochem/physiol Actions Peroxisome proliferator-activated receptor α (PPARα) agonist
  • Clinical Use Hyperlipidaemia
  • Drug interactions Potentially hazardous interactions with other drugs
    Antibacterials: increased risk of myopathy with daptomycin - try to avoid concomitant use.
    Anticoagulants: enhances effect of coumarins and phenindione. Dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INR.
    Antidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureas.
    Colchicine: possible increased risk of myopathy.
    Lipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe (Do not exceed 10 mg of simvastatin and 20 mg of rosuvastatin.1 ) - avoid with ezetimibe.
  • Metabolism Approximately 30-75% of a single dose administered to volunteers was excreted in the urine in 72 hours, either as unchanged ciprofibrate (20-25% of the total excreted) or as a glucuronide conjugate. Subjects with moderate renal impairment excreted on average 7% of a single dose as unchanged ciprofibrate over 96 hours, compared with 6.9% in normal subjects. In subjects with severe insufficiency this was reduced to 4.7%.
Ciprofibrate Preparation Products And Raw materials
Raw materials
Preparation Products
Global(367)Suppliers
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:+86-0371-55170693<br/>+86-19937530512
  • Email:info@tianfuchem.com
  • Country:China
  • ProdList:21628
  • Advantage:55
  • Supplier:
    career henan chemical co
  • Tel:+86-0371-86658258<br/>+8613203830695
  • Email:sales@coreychem.com
  • Country:China
  • ProdList:29859
  • Advantage:58
  • Supplier:
    Alchem Pharmtech,Inc.
  • Tel:8485655694
  • Email:sales@alchempharmtech.com
  • Country:United States
  • ProdList:63687
  • Advantage:58
Ciprofibrate Spectrum
52214-84-3, CiprofibrateRelated Search:
  • Intracellular receptor
  • API
  • 抑制剂
  • 配体家族
  • 黄金展台
  • 生物医药-医药原料
  • 原料
  • 医药原料
  • 化工原料
  • 医药化工原料
  • 医药、农药及染料中间体
  • 医药
  • 医用原料
  • 医药原料药
  • 有机化工
  • 化工原料
  • 中间体
  • 细胞生物学试剂
  • 细胞信号和神经生物学
  • 细胞生物学
  • 医药中间体
  • 药物
  • 心脑血管药物
  • 降血脂药
  • BioChemical
  • Cell Biology
  • Cell Signaling and Neuroscience
  • PPAR and RXR Regulators
  • Gene Regulation and Expression
  • C13H14Cl2O3
  • 环丙贝特,10 MM DMSO 溶液
  • 环丙贝特标准品
  • 环丙贝特/氯环丙妥明
  • 环丙贝特, 一种PPAR Α 激动剂
  • 环丙贝特 EP标准品
  • 环丙贝特系统适用性 EP标准品
  • PPAR激动剂(CIPROFIBRATE)
  • 2-[4-(2,2-二氯环丙基)苯氧]-2-甲基丙酸
  • 氯环丙妥明
  • 环丙贝特杂质
  • 环丙贝特.2-[4-(2.2-二氯环丙基)苯氧基]-2-甲基-丙酸
  • 环丙贝特 英文名称
  • 2-二氯环丙基)苯氧基]-2-甲基丙酸
  • 环丙贝特,>98.0%(GC)
  • 2-[4-(2,2-二氯环丙基)苯氧基]-2-甲基丙酸
  • 环丙贝特
  • 52214-84-3
  • Ciprofibrate - Bio-X ?
  • Ciprofibrate, 10 mM in DMSO
  • Ciprofibrate Impurity
  • Ciprofibrate, ≥ 98.0%
  • Ciprofibrate Ciprofibrate(API)
  • 2-[4-[(1RS)-2,2-dichlorocyclopropyl]phenoxy]-2-methylpropanoicacid
  • Ciprofibrate/2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid
  • Ciprofibric acid
  • CiprofibrateQ: What is Ciprofibrate Q: What is the CAS Number of Ciprofibrate Q: What is the storage condition of Ciprofibrate Q: What are the applications of Ciprofibrate
  • Ciprofibrate USP/EP/BP
  • Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-